1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
FEATURED COMPANIES
- AstraZeneca Plc
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- Endo International Plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
Global Oral Cancer Therapeutics Market: About this market
The oral cancer therapeutics market analysis considers sales from both targeted therapy and chemotherapy. Our analysis also considers the sales of oral cancer therapeutics in Asia, Europe, North America, and ROW. In 2018, the targeted therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as encourage additional R&D investments and exploit interactions and technological capabilities will play a significant role in the targeted therapy segment to maintain its market position. Also, our global oral cancer therapeutics market report looks at factors such as increasing incidence and prevalence of oral cancer, increasing risk factors for oral cancer, growing awareness about oral cancer. However, side-effects of chemotherapeutics, adoption of alternative treatment option as first-line therapy, high treatment cost targeted therapies may hamper the growth of the oral cancer therapeutics industry over the forecast period.
Global Oral Cancer Therapeutics Market: Overview
Growing awareness about oral cancer
Several public and private organizations are taking the initiative to increase awareness about oral cancer. These organization aims to raise awareness about the disease to get more mouth cancers diagnosed at an early stage. The organizations educate the mass about the risk factors, and signs and symptoms and encouraging them to discuss this with their dental professionals. CDC continues its effort to promote oral cancer research, surveillance and comprehensive educational sources for healthcare professionals and the public by increasing excise taxes on tobacco and alcohol products to targeted funding for oral cancer prevention program. This will lead to the expansion of the global oral cancer therapeutics market at a CAGR of over 8% during the forecast period.
Development of nanotechnology-based drug delivery systems
Targeted drug delivery systems by nanoparticles are expected to be the most promising multi-functional platform in cancer therapeutics. The emergence of nanoparticles in drug delivery provided solutions to many challenges such as enhanced and effective drug loading, transportation and controlled drug release, and precise targeting of tumor-sites. They also support in the development of toxic-free atmosphere by reducing the quantity of the drug to a concentration at the surrounding area of the targeted site making it more efficient. This development is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global oral cancer therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading oral cancer therapeutics manufacturers. These include AstraZeneca Plc, Bristol-Myers Squibb Co., Eli Lilly and Co., Endo International Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd.
Also, the oral cancer therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The oral cancer therapeutics market analysis considers sales from both targeted therapy and chemotherapy. Our analysis also considers the sales of oral cancer therapeutics in Asia, Europe, North America, and ROW. In 2018, the targeted therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as encourage additional R&D investments and exploit interactions and technological capabilities will play a significant role in the targeted therapy segment to maintain its market position. Also, our global oral cancer therapeutics market report looks at factors such as increasing incidence and prevalence of oral cancer, increasing risk factors for oral cancer, growing awareness about oral cancer. However, side-effects of chemotherapeutics, adoption of alternative treatment option as first-line therapy, high treatment cost targeted therapies may hamper the growth of the oral cancer therapeutics industry over the forecast period.
Global Oral Cancer Therapeutics Market: Overview
Growing awareness about oral cancer
Several public and private organizations are taking the initiative to increase awareness about oral cancer. These organization aims to raise awareness about the disease to get more mouth cancers diagnosed at an early stage. The organizations educate the mass about the risk factors, and signs and symptoms and encouraging them to discuss this with their dental professionals. CDC continues its effort to promote oral cancer research, surveillance and comprehensive educational sources for healthcare professionals and the public by increasing excise taxes on tobacco and alcohol products to targeted funding for oral cancer prevention program. This will lead to the expansion of the global oral cancer therapeutics market at a CAGR of over 8% during the forecast period.
Development of nanotechnology-based drug delivery systems
Targeted drug delivery systems by nanoparticles are expected to be the most promising multi-functional platform in cancer therapeutics. The emergence of nanoparticles in drug delivery provided solutions to many challenges such as enhanced and effective drug loading, transportation and controlled drug release, and precise targeting of tumor-sites. They also support in the development of toxic-free atmosphere by reducing the quantity of the drug to a concentration at the surrounding area of the targeted site making it more efficient. This development is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global oral cancer therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading oral cancer therapeutics manufacturers. These include AstraZeneca Plc, Bristol-Myers Squibb Co., Eli Lilly and Co., Endo International Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd.
Also, the oral cancer therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- AstraZeneca Plc
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- Endo International Plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
PART 01: EXECUTIVE SUMMARYPART 07: CUSTOMER LANDSCAPEPART 09: DECISION FRAMEWORK
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY PRODUCT
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
List of Exhibits:
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- AstraZeneca Plc
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- Endo International Plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
The following companies are recognised as the key players in the global oral cancer therapeutics market: AstraZeneca Plc, Bristol-Myers Squibb Co., Eli Lilly and Co., Endo International Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of nanotechnology-based drug delivery systems.”
According to the report, one of the major drivers for this market is the growing awareness about oral cancer.
Further, the report states that one of the major factors hindering the growth of this market is the high treatment cost targeted therapies.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of nanotechnology-based drug delivery systems.”
According to the report, one of the major drivers for this market is the growing awareness about oral cancer.
Further, the report states that one of the major factors hindering the growth of this market is the high treatment cost targeted therapies.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
A selection of companies mentioned in this report includes:
- AstraZeneca Plc
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- Endo International Plc
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Mylan NV
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown